Possible involvement of toll-like receptors in the pathogenesis of myasthenia gravis

Inflammation

Volumn 36, Issue 1, 2013, Pages 121-130

  Wang, Yu Zhong ^a,b   Yan, Mei ^a   Tian, Fa Fa ^a   Zhang, Jun Mei ^a   Liu, Qun ^a   Yang, Huan ^a   Zhou, Wen Bin ^a   Li, Jing ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b JINING MEDICAL UNIVERSITY   (China)

Author keywords

innate immunity; myasthenia gravis; Toll like receptors

Indexed keywords

MESSENGER RNA; METHYLPREDNISOLONE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 10; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9;

ADULT; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG PULSE THERAPY; FEMALE; HUMAN; HUMAN CELL; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MALE; MYASTHENIA GRAVIS; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

HUMANS; LEUKOCYTES, MONONUCLEAR; MYASTHENIA GRAVIS; PREDNISONE; RNA, MESSENGER; TOLL-LIKE RECEPTOR 9; TOLL-LIKE RECEPTORS;

EID: 84872924539     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-012-9526-6     Document Type: Article

References (32)

1. Conti-Fine, B.M., M. Milani, and H.J. Kaminski. 2006. Myasthenia gravis: past, present, and future. The Journal of Clinical Investigation 116: 2843-2854. (Pubitemid 44684466)
2. Lindstrom, J.M., M.E. Seybold, V.A. Lennon, S. Whittingham, and D.D. Duane. 1976. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 26: 1054-1059.
3. Hoch, W., J. McConville, S. Helms, J. Newsom-Davis, A. Melms, and A. Vincent. 2001. Auto-Antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nature Medicine 7: 365-368. (Pubitemid 32224355)
4. McGettrick, A.F., and L.A. O'Neill. 2007. Toll-like receptors: key activators of leucocytes and regulator of haematopoiesis. British Journal of Haematology 139: 185-193. (Pubitemid 47493098)
5. Zarember, K.A., and P.J. Godowski. 2002. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. The Journal of Immunology 168: 554-561. (Pubitemid 34049553)
6. Takeda, K. and S. Akira. 2007. Toll-like receptors. Current Protocols in Immunology. Chapter 14: Unit 14 12.
7. Kawai, T., and S. Akira. 2007. TLR signaling. Seminars in Immunology 19: 24-32. (Pubitemid 46498752)
8. Medzhitov, R., P. Preston-Hurlburt, E. Kopp, A. Stadlen, C. Chen, S. Ghosh, and C.A. Janeway Jr. 1998. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Molecular Cell 2: 253-258. (Pubitemid 128373651)
9. Devaraj, S., M.R. Dasu, J. Rockwood, W. Winter, S.C. Griffen, and I. Jialal. 2008. Increased Toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state. The Journal of Clinical Endocrinology and Metabolism 93: 578-583. (Pubitemid 351240834)
10. Ehlers, M., H. Fukuyama, T.L. McGaha, A. Aderem, and J.V. Ravetch. 2006. TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. The Journal of Experimental Medicine 203: 553-561.
11. Zeuner, R.A., K.J. Ishii, M.J. Lizak, I. Gursel, H. Yamada, D.M. Klinman, and D. Verthelyi. 2002. Reduction of CpG-induced arthritis by suppressive oligodeoxynucleotides. Arthritis and Rheumatism 46: 2219-2224.
12. Deng, Y.N., and W.B. Zhou. 2007. Expression of TLR4 and TLR9 mRNA in Lewis rats with experimental allergic neuritis. Neuroimmunomodulation 14: 337-343. (Pubitemid 351737862)
13. Wang, Y.Z., Q.H. Liang, H. Ramkalawan, Y.L. Wang, Y.F. Yang, W.B. Zhou, F. Tian, J. Li, and H. Yang. 2012. Expression of Toll-like receptors 2, 4 and 9 in Patients with Guillain-Barré syndrome. Neuroimmunomodulation 19: 60-68.
14. Wang, Y.Z., Q.H. Liang, H. Ramkalawan, W. Zhang, W.B. Zhou, B. Xiao, F.F. Tian, H. Yang, J. Li, Y. Zhang, and N.A. Xu. 2011. Inactivation of TLR9 by a suppressive oligodeoxynucleotides can ameliorate the clinical signs of EAN. Immunological Investigations 41: 171-182.
15. Bernasconi, P., M. Barberis, F. Baggi, L. Passerini, M. Cannone, E. Arnoldi, L. Novellino, F. Cornelio, and R. Mantegazza. 2005. Increased Toll-like receptor 4 expression in thymus of myasthenic patients with thymitis and thymic involution. The American Journal of Pathology 167: 129-139. (Pubitemid 40884776)
16. Montero Vega, M.T., and A. de Andres Martin. 2008. Toll-like receptors: A family of innate sensors of danger that alert and drive immunity. Allergologia et Immunopathologia (Madr) 36: 347-357.
17. Jaretzki 3rd, A., R.J. Barohn, R.M. Ernstoff, H.J. Kaminski, J.C. Keesey, A.S. Penn, and D.B. Sanders. 2000. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55: 16-23.
18. Osserman, K.E., and G. Genkins. 1971. Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients. The Mount Sinai Journal of Medicine 38: 497-537.
19. Sharshar, T., S. Chevret, M. Mazighi, P. Chillet, G. Huberfeld, C. Berreotta, M. Houfani, and P. Gajdos. 2000. Validity and reliability of two muscle strength scores commonly used as endpoints in assessing treatment of myasthenia gravis. Journal of Neurology 247: 286-290. (Pubitemid 30223966)
20. Rozkova, D., R. Horvath, J. Bartunkova, and R. Spisek. 2006. Glucocorticoids severely impair differentiation and antigen presenting function of dendritic cells despite upregulation of Toll-like receptors. Clinical Immunology 120: 260-271. (Pubitemid 44175897)
21. McCoy, C.E., S. Carpenter, E.M. Palsson-McDermott, L.J. Gearing, and L.A. O'Neill. 2008. Glucocorticoids inhibit IRF3 phosphorylation in response to Toll-like receptor-3 and -4 by targeting TBK1 activation. The Journal of Biological Chemistry 283: 14277-14285.
22. Roelofs, M.F., M.H. Wenink, F. Brentano, S. Abdollahi-Roodsaz, B. Oppers-Walgreen, P. Barrera, P.L. van Riel, L.A. Joosten, D. Kyburz, W.B. van den Berg, and T.R. Radstake. 2009. Type I interferons might form the link between Toll-like receptor (TLR) 3/7 and TLR4-mediated synovial inflammation in rheumatoid arthritis (RA). Annals of the Rheumatic Diseases 68: 1486-1493.
23. Kessel, A., R. Peri, T. Haj, A. Snir, G. Slobodin, E. Sabo, I. Rosner, Y. Shoenfeld, and E. Toubi. 2011. IVIg attenuates TLR-9 activation in B cells from SLE patients. Journal of Clinical Immunology 31: 30-38.
24. Marta, M., A. Andersson, M. Isaksson, O. Kampe, and A. Lobell. 2008. Unexpected regulatory roles of TLR4 and TLR9 in experimental autoimmune encephalomyelitis. European Journal of Immunology 38: 565-575.
25. Muzio, M., N. Polentarutti, D. Bosisio, P.P. Manoj Kumar, and A. Mantovani. 2000. Toll-like receptor family and signalling pathway. Biochemical Society Transactions 28: 563-566.
26. Chow, J.C., D.W. Young, D.T. Golenbock, W.J. Christ, and F. Gusovsky. 1999. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. The Journal of Biological Chemistry 274: 10689-10692. (Pubitemid 29191043)
27. Lee, K.S., C.A. Scanga, E.M. Bachelder, Q. Chen, and C.M. Snapper. 2007. TLR2 synergizes with both TLR4 and TLR9 for induction of the MyD88-dependent splenic cytokine and chemokine response to Streptococcus pneumoniae. Cellular Immunology 245: 103-110. (Pubitemid 46921170)
28. Krieg, A.M. 2002. CpG motifs in bacterial DNA and their immune effects. Annual Review of Immunology 20: 709-760. (Pubitemid 34293438)
29. Riccardi, C., S. Bruscoli, and G. Migliorati. 2002. Molecular mechanisms of immunomodulatory activity of glucocorticoids. Pharmacological Research 45: 361-368. (Pubitemid 35304501)
30. Chinenov, Y., and I. Rogatsky. 2007. Glucocorticoids and the innate immune system: crosstalk with the Toll-like receptor signaling network. Molecular and Cellular Endocrinology 275: 30-42. (Pubitemid 47260712)
31. Lepelletier, Y., R. Zollinger, C. Ghirelli, F. Raynaud, R. Hadj-Slimane, A. Cappuccio, O. Hermine, Y.J. Liu, and V. Soumelis. 2010. Toll-like receptor control of glucocorticoid-induced apoptosis in human plasmacytoid predendritic cells (pDCs). Blood 116: 3389-3397.
32. Bhattacharyya, S., D.E. Brown, J.A. Brewer, S.K. Vogt, and L.J. Muglia. 2007. Macrophage glucocorticoid receptors regulate Toll-like receptor 4-mediated inflammatory responses by selective inhibition of p38 MAP kinase. Blood 109: 4313-4319. (Pubitemid 46743398)